

# Anne Margarita Dyrhol-Riise

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9100635/publications.pdf>

Version: 2024-02-01

30  
papers

864  
citations

516710

16  
h-index

501196

28  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1656  
citing authors

#	ARTICLE	IF	CITATIONS
1	Probiotics to HIV-Infected Immunological Nonresponders: Altered Mucosal Immunity and Microbial Diversity Restricted to Ileum. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2022, 89, 77-86.	2.1	3
2	Human Immunodeficiency Virus-Infected Immunological Nonresponders Have Colon-Restricted Gut Mucosal Immune Dysfunction. <i>Journal of Infectious Diseases</i> , 2022, 225, 661-674.	4.0	16
3	Clinical characteristics and outcomes in hospitalized adult influenza patients: an observational study from Norway 2014-2018. <i>Infectious Diseases</i> , 2022, 54, 367-377.	2.8	3
4	Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement. <i>Journal of Internal Medicine</i> , 2021, 289, 523-531.	6.0	76
5	What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. <i>BMJ Open</i> , 2021, 11, e043887.	1.9	51
6	Increased inflammatory markers reflecting fibrogenesis are independently associated with cardiac involvement in hospitalized COVID-19 patients. <i>Journal of Infection</i> , 2021, 82, 186-230.	3.3	0
7	Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns. <i>Journal of Internal Medicine</i> , 2021, 290, 677-692.	6.0	20
8	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	3.9	84
9	Cardiac function is normal in most patients recovered from COVID-19. <i>European Heart Journal</i> , 2021, 42, .	2.2	0
10	Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4+ T Cells in HIV-Infected Immunological Non-Responders. <i>Frontiers in Immunology</i> , 2021, 12, 744155.	4.8	3
11	A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. <i>Nature Communications</i> , 2021, 12, 6774.	12.8	34
12	Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. <i>Scientific Reports</i> , 2021, 11, 23205.	3.3	26
13	Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. <i>Scientific Reports</i> , 2020, 10, 21697.	3.3	65
14	Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. <i>Journal of Infection</i> , 2020, 81, e41-e43.	3.3	129
15	Mycobacterial antigens in pleural fluid mononuclear cells to diagnose pleural tuberculosis in HIV co-infected patients. <i>BMC Infectious Diseases</i> , 2020, 20, 459.	2.9	6
16	Burden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy337.	0.9	12
17	IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting. <i>Scientific Reports</i> , 2019, 9, 3871.	3.3	11
18	In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry. <i>Journal of Immunological Methods</i> , 2018, 460, 93-100.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Unexplained chronic liver disease in Ethiopia: a cross-sectional study. BMC Gastroenterology, 2018, 18, 27.	2.0	25
20	The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study. BMC Infectious Diseases, 2017, 17, 228.	2.9	13
21	T Cell Responses and Regulation and the Impact of <i>In Vitro</i> IL-10 and TGF- $\beta$ 2 Modulation During Treatment of Active Tuberculosis. Scandinavian Journal of Immunology, 2017, 85, 138-146.	2.7	11
22	Multidrug-resistant tuberculosis in Norway: a nationwide study, 1995–2014. International Journal of Tuberculosis and Lung Disease, 2016, 20, 786-792.	1.2	12
23	Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection. Clinical and Experimental Immunology, 2015, 179, 454-465.	2.6	44
24	IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. Journal of Infection, 2015, 70, 381-391.	3.3	76
25	HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2-year follow-up; a Norwegian prospective multicenter study. BMC Infectious Diseases, 2014, 14, 667.	2.9	19
26	Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway. International Journal of Tuberculosis and Lung Disease, 2014, 18, 180-187.	1.2	5
27	Screening for latent tuberculosis in Norwegian health care workers: high frequency of discordant tuberculin skin test positive and interferon-gamma release assay negative results. BMC Public Health, 2013, 13, 353.	2.9	20
28	T Regulatory Cells and Immune Activation in Mycobacterium tuberculosis Infection and the Effect of Preventive Therapy. Scandinavian Journal of Immunology, 2011, 73, 234-242.	2.7	49
29	Use of interferon gamma-based assay to diagnose tuberculosis infection in health care workers after short term exposure. BMC Infectious Diseases, 2009, 9, 60.	2.9	18
30	School based screening for tuberculosis infection in Norway: comparison of positive tuberculin skin test with interferon-gamma release assay. BMC Infectious Diseases, 2008, 8, 140.	2.9	22